Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 May 30:7:322.
doi: 10.1186/1756-0500-7-322.

Epiphora in lung cancer patients receiving docetaxel: a case series

Tomoko Yamagishi, Nobuaki Ochi, Hiromichi Yamane, Satoshi Hasebe, Nagio Takigawa  1
Affiliations
Case Reports

Epiphora in lung cancer patients receiving docetaxel: a case series

Tomoko Yamagishi et al. BMC Res Notes. .

Abstract

Background: Docetaxel is a key antineoplastic drug for treatment of non-small cell lung cancer. Ocular adverse events of docetaxel include epiphora (excess tearing) and conjunctivitis. Epiphora has been reported to be associated with canalicular and nasolacrimal duct stenosis, but it is not necessarily caused by lacrimal duct obstruction.

Case presentation: We encountered three Japanese non-small cell lung cancer patients who developed epiphora after the administration of docetaxel-based chemotherapy. One patient with lacrimal puncta stenosis showed improvement with probing and irrigation. The other two patients resolved following cessation of docetaxel or administration of artificial tears.

Conclusion: As epiphora can interfere with activities of daily life and negatively affect quality of life, it is important for thoracic oncologists to be aware of this adverse event.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Slit-lamp examination of the left eye and irrigation of the nasolacrimal duct. Slit-lamp examination of the left eye revealed stenosis of the lower lacrimal puncta, which the arrow pointed to (A). Probing and irrigation of the nasolacrimal duct was performed (B).
See this image and copyright information in PMC

References

    1. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103. - PubMed
    1. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13:2643–2655. - PubMed
    1. Esmaeli B, Hortobagyi GN, Esteva FJ, Booser D, Ahmadi MA, Rivera E, Arbuckle R, Delpassand E, Guerra L, Valero V. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology. 2002;109:1188–1191. doi: 10.1016/S0161-6420(02)00989-2. - DOI - PubMed
    1. Esmaeli B, Hidaji L, Adinin RB, Faustina M, Coats C, Arbuckle R, Rivera E, Valero V, Tu SM, Ahmadi MA. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 2003;98:504–507. doi: 10.1002/cncr.11527. - DOI - PubMed
    1. Chan A, Su C, de Boer RH, Gajdatsy A. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. J Clin Oncol. 2013;31:2123–2127. doi: 10.1200/JCO.2012.45.6574. - DOI - PubMed

Publication types